|
1 |
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial
Hörner, Manuel. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2026
|
|
|
|
2 |
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry
Hörner, Manuel. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2026
|
|
|
|
3 |
The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer – the SERAPHINA study
Schneeweiss, Andreas. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2025
|
|
|
|
4 |
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors
Braun, Tatjana. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2025
|
|
|
|
5 |
Therapy of early breast cancer: current status and perspectives
Tauber, Nikolas. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2025
|
|
|
6 |
Therapy of early breast cancer: current status and perspectives
Enthalten in Archives of gynecology and obstetrics 22.4.2025: 1-18
|
|
|
|
7 |
ENABLE – eine digitale therapiebegleitende Plattform für Patientinnen mit invasivem Mammakarzinom
Enthalten in Senologie Bd. 21, 2024, Nr. 04: 265-267
|
|
|
|
8 |
Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer
Enthalten in Archives of gynecology and obstetrics 2.3.2022: 1-11
|
|
|
|
9 |
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study
Wallwiener, Markus. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2019
|
|
|
|
10 |
Zirkulierende Tumorzellen, zirkulierende Tumor-DNA und zirkulierende microRNA beim metastasierten Mammakarzinom – oder: Welche Rolle spielt die Liquid Biopsy beim Brustkrebs?
Enthalten in Deutsche Zeitschrift für Onkologie Bd. 51, 2019, Nr. 02: 65-73
|
|
Administration
